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Summary
Over the past decade RNA interference (RNAi) has emerged as a natural mechanism for silencing
gene expression. This ancient cellular antiviral response can be exploited to allow specific inhibition
of the function of any chosen target gene. RNAi is proving to be an invaluable research tool,
allowing much more rapid characterization of the function of known genes. More importantly,
RNAi technology considerably bolsters functional genomics to aid in the identification of novel
genes involved in disease processes.
This review briefly describes the molecular principles underlying the biology of RNAi phenomenon
and discuss the main technical issues regarding optimization of RNAi experimental design.
Introduction
In 1998 Fire and coll. coined the term RNA interference
(RNAi) referring to the phenomenon of post-translational
silencing of gene expression that occurs in response to the
introduction of double-stranded RNA (dsRNA) into a cell
[1]. This phenomenon can result in highly specific sup-
pression of gene expression. RNAi technology is rapidly
spreading in research laboratories worldwide, as it is asso-
ciated with a number of practical and theoretic advantages
over preexisting methods of suppressing gene expression
(Table 1). RNAi promises to revolutionize key areas of
medical research, as demonstrated by the preliminary
findings obtained in the fields of cancer, infectious dis-
eases and neurodegenerative disorders. In this review the
principles underlying this phenomenon as well as the
technical challenges encountered while using RNAi for
research purposes are discussed.
The physiology of RNAi
Introduction of long dsRNA into a mammalian cell trig-
gers a vigorous nonspecific shutdown of transcription and
translation, in part due to activation of dsRNA-dependent
protein kinase-R (PKR) [2]. Activated PKR phosphorylates
the translation initiation factor EIF2: this effect, in associ-
ation with activation of Rnase-L and induction of inter-
feron production, halts protein synthesis and promotes
apoptosis. Overall, this is believed to represent an antivi-
ral defense mechanism [3]. Owing to this phenomenon,
initial observations of RNAi induced by long dsRNA in
plants [4] and the nematode Caenorhabditis elegans [1]
were at first applied to mammalian cells with little suc-
cess. In a breakthrough experience reported by Elbashir et
al., it was discovered that dsRNAs 21–23 nucleotides long
– termed small interfering RNAs (siRNAs) – could sup-
press mammalian gene expression in a highly specific
manner [5], pointing the way to gene silencing in mam-
malian cells.
RNAi is a highly conserved mechanism throughout taxo-
nomical species [6]. In addition to have an antiviral activ-
ity, RNAi is also believed to suppress the expression of
potentially harmful segments of the genome, such as
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genome by acting as insertional mutagens [7]. Though its
mechanisms are not fully elucidated, RNAi represents the
result of a multistep process (Figure 1). Upon entering the
cell, long dsRNAs are first processed by the RNAse III
enzyme Dicer [8]. This functional dimer contains helicase,
dsRNA binding, and PAZ (named after piwi, argonaute,
and zwille proteins) domains. Whereas the former two
domains are important for dsRNA unwinding and media-
tion of protein-RNA interactions, the function of the PAZ
domain species, is not completely elucidated [9,10]. Dicer
produces 21–23 nucleotide dsRNA fragments with two
nucleotide 3' end overhangs, i.e. siRNAs. Recently it has
been suggested that Dicer has functions other than dsRNA
cleavage that are required for siRNA-mediated RNAi in
mammals [11]. RNAi is mediated by the RNA-induced
silencing complex (RISC) which, guided by siRNA, recog-
nizes mRNA containing a sequence homologous to the
siRNA and cleaves the mRNA at a site located approxi-
mately in the middle of the homologous region [9]. Thus,
gene expression is specifically inactivated at a post-tran-
scriptional level. In C. elegans, Dicer has been shown to
interact with rde proteins. The rde proteins bind to long
dsRNA and are believed to present the long dsRNA to
Dicer for processing [12]. Mutants displaying a high
degree of resistance to RNAi have been reported to possess
mutations at rde-1 and rde-4 loci [13]. Given the highly
conserved nature of these enzymes, similar mutations
may be of significance in mammalian cells.
Besides gene silencing, RNAi might be involved in other
phenomena of gene regulation. DNA/RNA interactions
are known to influence DNA methylation. It appears that
RNAi can also function on this level by methylating
cytosines as well as CpG sequences more classically asso-
ciated with methylation. If the target sequence shares
homology with a promoter, transcriptional silencing may
occur via methylation. Moreover, RNA appears to interact
with chromatin domains, which may ultimately direct
DNA methylation. Studies of C. elegans have shown that
RNAi can spread among cells through mechanisms that
may not hinge upon siRNA [14]. The systemic RNA inter-
ference-deficient (sid) locus, sid-1, encodes a conserved
protein with a signal peptide sequence and 11 putative
transmembrane domains, suggesting that the sid-1 pro-
tein may act as a channel for long dsRNA, siRNA, or a cur-
rently undiscovered RNAi-related signal. Sid-1 mutants
retain cell-autonomous RNAi but fail to show spreading
of RNAi. It remains unclear whether this systemic RNAi
occurs in mammals, although a strong similarity is
reported between sid-1 and predicted human and mouse
proteins.
siRNA synthesis and delivery strategies
Several strategies for inducing siRNA-mediated gene
silencing have been developed, each of them presenting
specific advantages and disadvantages (Table 2).
Synthesis, purification, and annealing of siRNAs by indus-
trial chemical processes [15] is becoming increasingly
popular. This method is rapid and purity is generally high.
This may be the best approach for initial "proof of princi-
ple" experiments. In vitro siRNA synthesis is an alternative
and relies upon the T7-phage polymerase [16]. This
polymerase produces individual siRNA sense and anti-
sense strands that – once annealed – form siRNAs. Extra
nucleotides required by the T7 promoter are removed by
RNase digestion and cleaning steps. Otherwise, recom-
binant Rnase-III can be used to cleave long dsRNAs to pro-
duce multiple siRNAs [17]. Although technically easy, this
approach presents the drawback of the generation of non-
specific siRNAs. siRNAs can be produced by polymerase-
III promoter-based DNA plasmids or expression cassettes
[18]. These constructs produce small inverted repeats, sep-
arated by a spacer of three to nine nucleotides, termed
short hairpin RNAs (shRNAs), which are processed by
Dicer into siRNAs [19]. Transcription begins at a specific
initiation sequence, determined by the promoter used. In











Dominant negative mutants Stable suppression
Specific protein domains can be targeted
Needs transfection
Variable/unexpected effect
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Mechanism of RNA interference (RNAi). The appearance of double stranded (ds) RNA within a cell (e.g. as a consequence of 
viral infection) triggers a complex response, which includes among other phenomena (e.g. interferon production and its conse-
quences) a cascade of molecular events known as RNAi. During RNAi, the cellular enzyme Dicer binds to the dsRNA and 
cleaves it into short pieces of ~ 20 nucleotide pairs in length known as small interfering RNA (siRNA). These RNA pairs bind 
to the cellular enzyme called RNA-induced silencing complex (RISC) that uses one strand of the siRNA to bind to single 
stranded RNA molecules (i.e. mRNA) of complementary sequence. The nuclease activity of RISC then degrades the mRNA, 
thus silencing expression of the viral gene. Similarly, the genetic machinery of cells is believe to utilize RNAi to control the 
expression of endogenous mRNA, thus adding a new layer of post-transciptional regulation. RNAi can be exploited in the 
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polymerase-III promoter terminates with TTTT or TTTTT
[20]. The products are shRNAs that contain a series of uri-
dines at the 3' end, a feature that seems to favor RNAi [21].
Suppression of gene expression by RNAi is generally a
transient phenomenon [22]. Gene expression usually
recovers after 96 to 120 hours or 3 to 5 cell divisions after
transfection, which is likely due to dilution rather than
degradation of siRNAs. However, by introducing plasmids
which express siRNA and a selection gene, stable RNAi can
be sustained as long as two months after transfection [23].
Interest is growing in the use of viral vector-mediated
RNAi. Adenoviral and retroviral vectors have been
reported to produce siRNAs in vivo [24,25] and stable
RNAi is obtained using this method, though in the
absence of a selective pressure [26,27]. Virus-mediated
RNAi may circumvent some of the problems associated
with cells that are generally refractory to RNAi, such as
non-transformed primary cells [28]. At present, the ques-
tion of whether functional RNAi will continue in all prog-
eny of a cell with stable vector integration remains
unanswered.
Designing RNAi experiments
Several crucial considerations should be beard in mind
while designing RNAi experiments. The below examples
regard RNAi experiments performed with chemically syn-
thesized siRNA.
1. The first step is to design a suitable siRNA sequence. A
growing number of libraries of validated siRNAs directed
toward some frequently targeted genes are available.
However, if the gene of interest has not been targeted
using siRNA before, a novel siRNA must be developed. In
mammalian cells RNAi is mediated by 21- to 23-nucle-
otide siRNAs containing symmetrical two nucleotide 3'
overhangs. Given a siRNA sequence alone, it is not cur-
rently possible to predict the degree of gene knockdown
produced by a particular siRNA. Nevertheless, several
observations have been made that can be taken into
account to increase the probability of producing an effec-
tive siRNA. The chief variable is the gene target site. Gen-
erally, it is recommended that a target site located at least
100–200 nucleotides from the AUG initiation codon is
chosen. Targets within 50–100 nucleotides of the termi-
nation codon should instead be avoided. The 5' and 3'
untranslated region (UTR) should also be avoided, since
associated regulatory proteins might compromise RNAi.
This is just a general recommendation, as some siRNAs
targeting the 3' UTR have also been shown to induce RNAi
[29]. Numerous on-line design tools will produce a list of
suitable gene target sites. It is important to ensure that the
sequence is specific to the target gene by performing a
BLAST search in order to avoid cross reaction with
unwanted genes. As an example, Biocomputing at the
Whitehead Institute for Biomedical Research – a non-
profit independent research and educational institution
affiliated with the Massachusetts Institute of Technology –
is one of several organizations that has developed a freely
available web-based siRNA design tool.
2. The structural characteristics of the siRNA molecules are
another crucial aspect to be considered while designing
RNAi experiments. SiRNA of 21 nucleotides with 3'-d(TT)
or (UU) overhangs are considered the most effective [30].
Despite the fact that nucleotide-protein steric interactions
contribute to the relationship between siRNA length and
activity, the reason for this relationship is not completely
elucidated. For optimal siRNA secondary structure, the
GC ratio should ideally be between 45 and 55%, and mul-
tiple identical nucleotides in series, particularly poly(C)
and poly(G), should be avoided to determine any require-
ments for modification, such as fluorophore labeling to
allow for siRNA tracking and quantification of transfec-
tion efficiency.
Table 2: Comparison between siRNA delivery methods.
Method Advantages Drawbacks
Chemical or enzymatic synthesis Rapid




Enzymatic: variable purity & specificity
Chemical: expensive
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May be effective in cells resistant to transfection with 
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cells of interest. Several transfection reagents exist, the
most commonly used being liposomal or amine-based. In
some cases electroporation may be used, but cell toxicity
can be high with this technique [31]. Cell lines show var-
ying responses to different transfection reagents, and it
may be necessary to try more than one reagent or
approach. Transfection efficiency is optimized by titrating
cell density, transfection time, and the ratio of siRNA-to-
transfection reagent. The cell passage number and antibi-
otic use can also affect the efficiency of transfection.
4. Recently, experimental design features have been sug-
gested to guarantee the rigor of RNAi experiments [32].
Due to the high specificity of RNAi, a siRNA with a one-
nucleotide sequence mismatch can serve as a negative
control. If this approach is used, absence of homology
with other targets should be confirmed at the design stage.
It is important to remember that mismatched siRNAs
could target mutant gene sequences. Therefore loss of
functional target gene silencing should be demonstrated
to validate this approach. Alternatives include sequences
that preset no homology to any known gene. Some inves-
tigators have suggested that scrambled siRNA is not suffi-
ciently homologous to the target sequence to function as
an adequate control; therefore, they propose a combina-
tion of mismatched and scrambled controls [32]. A more
challenging functional control is to demonstrate the "res-
cue" of the target gene function following artificial overex-
pression of the target gene. Transfection of a plasmid
expressing the gene sequence to which a siRNA is targeted
results in production of mRNA that would also be targeted
by the siRNA. This problem can be overcome using plas-
mids containing silent mutations. This approach takes
advantage of degeneracy of gene coding, i.e., amino acids
are represented by more than one three-nucleotide codon
sequence. Rescue is achieved by expression of a protein
identical to the native protein from a nucleotide sequence
that differs from the native nucleotide sequence to which
the siRNA is targeted. Alternatively, siRNAs directed to the
3'-UTR can be used. Many researchers use more than one
siRNA, with each targeted to different areas of the gene
sequence. A consistent RNAi response using different siR-
NAs with a variety of targets within the gene sequence of
interest would increase confidence in experimental
results. Dose-respons characteristics should be deter-
mined and the lowest effective concentration of siRNA be
used to avoid nonspecific effects.
5. The effect of RNAi should be quantified at both the
mRNA and the protein level. The knockdown of a protein
should be probably evaluated after mRNA reduction has
been proved: in fact, a reduction in protein levels not
accompanied by a decrease in mRNA might indicate that
other mechanisms are at work, such as RNAi mediated by
microRNA. Northern blot analysis is considered by many
to be the gold standard. Real-time reverse transcriptase
polymerase chain reaction, incorporating internal con-
trols to quantify "housekeeping" gene transcript levels,
can also be used [33]. Protein knockdown can be con-
firmed by Western blot analysis, immunofluorescence,
flow cytometry and phenotypic and/or functional assays.
Although RNAi generally occurs within 24 h of transfec-
tion, both onset and duration of RNAi depend on the
turnover rate of the protein of interest, as well as the rate
of dilution and longevity of the siRNAs. The duration of
gene silencing can also be modified by factors such as the
concentration of serum in the culture medium, which
affects cell-cycle rate. It is therefore necessary to determine
the time course of any silencing observed under specific
conditions using the modalities discussed.
Conclusions
RNAi is now commonly used in biological and biomedi-
cal research to study the effect of blocking expression of a
given gene. As the effect is rarely complete, it is generally
termed a "knock-down" to distinguish it from the "knock-
out" achieved by deletion of the gene. Although signifi-
cant advances have been made as compared to previous
methods, RNAi has its own limitations. Not every
sequence works, most researchers reporting a success rate
of about one in three. Moreover, although the effects are
generally believed to be highly sequence-specific, some
doubts remain as to whether or not some of the observed
effects are "off target." Some residual activation of the
interferon system has been reported, as well as degrada-
tion of closely related, but non-identical, mRNAs. Never-
theless, RNAi remains the most promising functional
genomics tool recently developed. DNA microarray tech-
nology has now enabled the level of expression of every
gene in the genome to be determined under any condition
[34,35]. This has led to a huge accumulation of data on
genes whose expression is significantly altered in several
diseases. To take an example, large databases have been
established of genes that are pathologically regulated in
cancer. In some cases this has resulted in the identification
of key genes involved in tumor development and pro-
vided important new therapeutic targets. However, in
most cases the pattern of gene expression is far too com-
plex to allow for identification of the relatively small
number of misexpressed genes that are involved in caus-
ing or maintaining the disease rather than the much larger
number that are innocent bystanders. The ability of RNAi
to provide relatively easy ablation of gene expression has
opened up the possibility of using collections of siRNAs to
analyse the significance of hundreds or thousands of dif-
ferent genes whose expression is known to be upregulated
in a disease, given an appropriate tissue culture model of
that disease. Perhaps more important still is the possibil-
ity of using genome-wide collections of siRNAs, whetherPage 5 of 6
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avenues of research can rely upon RNAi libraries. First, in
a high-throughput manner each gene in the genome is
knocked-down one at a time and the cells or organism
scored for a desired outcome, such as death of a cultured
cancer cell but not a normal cell. Due to the very large
numbers of assays required to screen all 35–50,000 genes
in the human genome, this approach is highly labor-
intensive and time consuming. The other approach is to
use large pools of RNAi viral vectors and apply a selective
pressure that only cells with the desired change in behav-
ior can survive. The identity of the genes knocked-down in
the surviving cells can then be identified by sequencing
the RNA interference vectors that they carry. Both
approaches show consider-able promise in identifying
novel genes that may make important therapeutic targets
for inhibition either by conventional drug discovery
methods or, more intriguingly, by RNA interference itself.
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